Skip to main content
ABBOTT LABORATORIES logo

ABBOTT LABORATORIES — Investor Relations & Filings

Ticker · ABT ISIN · US0028241000 LEI · HQD377W2YR662HK5JX27 US Manufacturing
Open in API
Filings indexed 4,256 across all filing types
Latest filing 2016-07-27 Director's Dealing
Country US United States of America
Listing US ABT

About ABBOTT LABORATORIES

https://www.abbott.com

Abbott Laboratories is a global healthcare company that discovers, develops, manufactures, and sells a broad portfolio of life-changing technologies. The company's operations are focused on four core businesses: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. The Medical Devices division offers solutions for cardiovascular health, diabetes care (including the FreeStyle Libre continuous glucose monitoring system), and neuromodulation. The Diagnostics segment provides a wide range of in vitro diagnostic systems and tests for hospitals, laboratories, and clinics. The Nutrition business develops and markets science-based nutritional products for people of all ages, with leading brands such as Similac, PediaSure, Ensure, and Glucerna. The Established Pharmaceuticals division provides a portfolio of branded generic medicines to consumers in emerging markets.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2016-07-27 English
FORM 4 -
Director's Dealing
2016-07-27 English
FORM 4 -
Director's Dealing
2016-07-27 English
FORM 4 -
Director's Dealing
2016-07-27 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 20, 2016, by Abbott Laboratories. It specifically references Item 2.02, which pertains to "Results of Operations and Financial Condition," and includes a press release announcing second quarter 2016 results. The text mentions non-GAAP financial measures and management's discussion of performance, typical of earnings announcements. The document is relatively short (4003 characters) and primarily serves to announce the earnings results via a press release (Exhibit 99.1). This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights. It is not a full quarterly report (IR) or annual report (10-K), nor is it a certification or regulatory filing. Therefore, the correct classification is ER with high confidence.
2016-07-20 English
425 Filing
Call Transcript Classification · 100% confidence The document is a transcript of a conference call held by Abbott Laboratories discussing their second-quarter 2016 earnings and strategic acquisition of St. Jude Medical. It includes detailed remarks from the CEO and CFO, as well as a Q&A session with analysts. The content focuses on financial performance, business strategy, and acquisition updates, typical of an earnings call transcript. The presence of multiple speakers, analyst questions, and detailed financial discussion confirms this is a Call Transcript (CT). The document length (15,000 characters) and detailed content further support this classification rather than a brief earnings release or announcement.
2016-07-20 English

Browse filings by year

33 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.